Clinical Trial

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Study acronym: HyaluronicAcid
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-18
notable Primary completion pushed: 2026-10 -> 2027-07 2026-06-18
minor Completion pushed: 2027-10 -> 2028-07 2026-06-18
Trial Details
NCT Number NCT06325566
Lead Sponsor Mesoblast, Ltd.
Conditions Degenerative Disc Disease
Enrollment 300 participants
Start Date 2024-07-03
Primary Completion 2027-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-17